Search
Now showing items 1-5 of 5
Exploring the Association Between Suicidal Thoughts, Self-Injury, and GLP-1 Receptor Agonists in Weight Loss Treatments: Insights from Pharmacovigilance Measures and Unmasking Analysis
(2024-05)
Introduction: The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). Aim: The aim of this work was to analyse adverse drug reports (ADRs) from the ...
Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions
(2024-03-22)
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical success, the precise mechanisms ...
Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals
(2022-04-02)
‘Smart drugs’ (also known as ‘nootropics’ and ‘cognitive enhancers’ [CEs]) are being used by healthy subjects (i.e. students and workers) typically to improve memory, attention, learning, executive functions and vigilance, ...
New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review
(2021-05-01)
The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range ...
The clinical challenges of synthetic cathinones
(2019-11-01)
Within the new psychoactive substances (NPS) scenario, several hundreds of different molecules, mostly including synthetic cannabinoids and cathinones, have so far been identified. The aims of the paper were to: (a) identify ...